España
India
Italia
대한민ęµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민ęµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Regeneron Pharmaceuticals
REGN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$744.50
1.15
0.15%
At close: -
$744.50
0
0.00%
After Hours: 4:33 PM EDT
Get Report
Comment
Regeneron Pharmaceuticals (REGN) Forecast
News
Earnings
Regeneron Pharmaceuticals (REGN) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock
Regeneron Pharmaceuticals Stock (NASDAQ: REGN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, November 19, 2024
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Benzinga Insights
Monday, November 18, 2024
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Benzinga Insights
Friday, November 15, 2024
CNBC Halftime Report Final Trades: Berkshire ...
Benzinga Newsdesk
Check Out What Whales Are Doing With REGN
Benzinga Insights
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Vandana Singh
Wolfe Research Initiates Coverage On Regenero...
Benzinga Newsdesk
Dupixent's sBLA Resubmission Accepted By FDA;...
Benzinga Newsdesk
Thursday, November 14, 2024
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Benzinga Insights
Citigroup Initiates Coverage On Regeneron Pha...
Benzinga Newsdesk
Wednesday, November 13, 2024
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Vandana Singh
Wednesday, November 06, 2024
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
Benzinga Insights
Oppenheimer Maintains Outperform on Regeneron...
Benzinga Newsdesk
Regeneron And Sanofi's Dupixent Receives EU A...
Benzinga Newsdesk
Tuesday, November 05, 2024
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Vandana Singh
Monday, November 04, 2024
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Benzinga Insights
Friday, November 01, 2024
Morgan Stanley Maintains Overweight on Regene...
Benzinga Newsdesk
RBC Capital Maintains Outperform on Regeneron...
Benzinga Newsdesk
Barclays Maintains Overweight on Regeneron Ph...
Benzinga Newsdesk
BMO Capital Maintains Outperform on Regeneron...
Benzinga Newsdesk
Truist Securities Maintains Buy on Regeneron ...
Benzinga Newsdesk
Piper Sandler Maintains Overweight on Regener...
Benzinga Newsdesk
Thursday, October 31, 2024
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Vandana Singh
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Piero Cingari
Regeneron shares are trading lower following ...
Benzinga Newsdesk
Regeneron Sees FY24 Non-GAAP Gross Margin On ...
Benzinga Newsdesk
Regeneron Pharmaceuticals Q3 2024 Adj. EPS $1...
Benzinga Newsdesk
Wednesday, October 30, 2024
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Vandana Singh
Monday, October 28, 2024
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
Vandana Singh
Friday, October 25, 2024
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Vandana Singh
RBC Capital Reiterates Outperform on Regenero...
Benzinga Newsdesk
Thursday, October 24, 2024
Evercore ISI Group Maintains Outperform on Re...
Benzinga Newsdesk
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
Benzinga Insights
JP Morgan Maintains Overweight on Regeneron P...
Benzinga Newsdesk
Regeneron And Sanofi To Present Phase 3 LIBER...
Benzinga Newsdesk
Wednesday, October 23, 2024
A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
Benzinga Insights
Cantor Fitzgerald Reiterates Neutral on Regen...
Benzinga Newsdesk
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Benzinga Insights
Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
Market Whales and Their Recent Bets on REGN Options
Benzinga Insights
Barclays Maintains Overweight on Regeneron Ph...
Benzinga Newsdesk
Tuesday, October 22, 2024
Wells Fargo Maintains Overweight on Regeneron...
Benzinga Newsdesk
'Amgen To Launch US Eylea Biosimilar After Ru...
Benzinga Newsdesk
RBC Capital Reiterates Outperform on Regenero...
Benzinga Newsdesk
Watching Regeneron Pharmaceuticals; Hearing C...
Benzinga Newsdesk
Wednesday, October 16, 2024
Truist Securities Maintains Buy on Regeneron ...
Benzinga Newsdesk
Friday, October 11, 2024
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
MarketBeat
Thursday, October 10, 2024
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Benzinga Insights
What the Options Market Tells Us About Regeneron Pharmaceuticals
Benzinga Insights
Wednesday, October 09, 2024
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Vandana Singh
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch